Bladder cancer is the ninth most common cancer worldwide and is the thirteenth most common cause of cancer-associated mortality 1 . Non-muscle-invasive bladder cancer (NMIBC) is the most frequently diagnosed type of bladder cancer; ~75% of bladder cancers are NMIBC. The mainstay of NMIBC management is transurethral resection of bladder tumour (TURBT). NMIBC is stratified into low-risk, intermediate-risk, and high-risk categories using clinical and pathological factors. In the UK, intermediate-risk NMIBC is treated with adjuvant chemotherapy, whereas high-risk NMIBC is treated with adjuvant immunotherapy 2 . Neoadjuvant chemoablation has been described but is not the standard of care within NMIBC guidelines owing to limited level 1 evidence 3, 4 . A single post-TURBT instillation of chemotherapy as adjuvant therapy within 24 hours, but ideally within 6 hours, reduces the relative risk of recurrence by 35% (HR 0.65; 95% CI 0.58-0.74), according to the results of an individual patient data meta-analysis of . A course of intravesical chemotherapy is recommended for intermediate-risk NMIBC and reduces the relative risk of recurrence by 44% (HR 0.56; 6 . Mitomycin C (MMC), a cytotoxic antibiotic that induces cell death by alkylation and cross linking of DNA, is the most commonly used intravesical chemotherapy 7, 8 . Its molecular mass of 334 kDa minimizes the risk of systemic absorption and toxic effects, such as myelosuppression and pulmonary toxic effects 8 . Adverse events following intravesical delivery of MMC are predominantly local irritative voiding symptoms, which are reported in up to 39% of patients 9 . Evidence exists for alternative agents including epirubicin and doxorubicin, which have not been as commonly adopted as MMC owing to less compelling evidence, although studies have suggested that gemcitabine is efficacious and could be an alternative to MMC [10] [11] [12] . Intravesical BCG is recommended for high-risk NMIBC as an induction course of once-weekly instillations for 6 weeks followed by a maintenance regime of three once-weekly instillations at 3 and 6 months and then every subsequent 6 months for up to 3 years 13 . Maintenance BCG has been shown to increase absolute survival advantage by 5% at 5 years compared with induction BCG alone, supporting the use of maintenance treatment 13 . However, up to 65% of patients treated with BCG report local toxic effects, and 12% of patients do not complete maintenance therapy 14 . Since 2012, availability of BCG has become an issue in some countries, and production of the Connaught strain is expected to cease in 2019, further limiting availability 15 . Thus, the Abstract | Non-muscle-invasive bladder cancer (NMIBC), the most prevalent type of bladder cancer, accounts for ~75% of bladder cancer diagnoses. This disease has a 50% risk of recurrence and 20% risk of progression within 5 years, despite the use of intravesical adjuvant treatments (such as BCG or mitomycin C) that are recommended by clinical guidelines. Intravesical device-assisted therapies, such as radiofrequency-induced thermochemotherapeutic effect (RITE), conductive hyperthermic chemotherapy , and electromotive drug administration (EMDA), have shown promising efficacy. These device-assisted treatments are an attractive alternative to BCG, as issues with supply have been a problem in some countries. RITE might be an effective treatment option for some patients who have experienced BCG failure and are not candidates for radical cystectomy. Data from trials using EMDA suggest that it is effective in high-risk disease but requires further validation, and results of randomized trials are eagerly awaited for conductive hyperthermic chemotherapy. Considerable heterogeneity in patient cohorts, treatment sessions, use of maintenance regimens, and single-arm study design makes it difficult to draw solid conclusions, although randomized controlled trials have been reported for RITE and EMDA. 
. Neoadjuvant chemoablation has been described but is not the standard of care within NMIBC guidelines owing to limited level 1 evidence 3, 4 . A single post-TURBT instillation of chemotherapy as adjuvant therapy within 24 hours, but ideally within 6 hours, reduces the relative risk of recurrence by 35% (HR 0.65; 95% CI 0.58-0.74), according to the results of an individual patient data meta-analysis of low-risk, intermediate-risk, and high-risk NMIBC 5 . A course of intravesical chemotherapy is recommended for intermediate-risk NMIBC and reduces the relative risk of recurrence by 44% (HR 0.56; 95% CI 0.48-0.65) 6 . Mitomycin C (MMC), a cytotoxic antibiotic that induces cell death by alkylation and cross linking of DNA, is the most commonly used intravesical chemotherapy 7, 8 . Its molecular mass of 334 kDa minimizes the risk of systemic absorption and toxic effects, such as myelosuppression and pulmonary toxic effects 8 . Adverse events following intravesical delivery of MMC are predominantly local irritative voiding symptoms, which are reported in up to 39% of patients 9 . Evidence exists for alternative agents including epirubicin and doxorubicin, which have not been as commonly adopted as MMC owing to less compelling evidence, although studies have suggested that gemcitabine is efficacious and could be an alternative to MMC [10] [11] [12] . Intravesical BCG is recommended for high-risk NMIBC as an induction course of once-weekly instillations for 6 weeks followed by a maintenance regime of three once-weekly instillations at 3 and 6 months and then every subsequent 6 months for up to 3 years 13 . Maintenance BCG has been shown to increase absolute survival advantage by 5% at 5 years compared with induction BCG alone, supporting the use of maintenance treatment 13 . However, up to 65% of patients treated with BCG report local toxic effects, and 12% of patients do not complete maintenance therapy 14 . Since 2012, availability of BCG has become an issue in some countries, and production of the Connaught strain is expected to cease in 2019, further limiting availability 15 . Thus, the development of alternative intravesical treatments for bladder cancer is imperative. Despite the use of adjuvant therapies, up to 52% of patients with high-risk NMIBC will have disease recurrence, and up to 20% will progress to muscle-invasive bladder cancer (MIBC) within 5 years 16 . Radical cystectomy is the standard-of-care treatment after BCG failure, although rechallenging with further BCG remains an option according to National Comprehensive Cancer Network guidelines 2, 17 . Developments for the treatment of NMIBC have focused on optimizing the delivery of established therapies or potentiating the effects of chemotherapy using intravesical device-assisted technology to deliver hyperthermia to the bladder wall or circulating chemotherapy and ionization of chemotherapy to improve drug tissue penetration. The three most used devices are radiofrequency-induced thermochemotherapeutic effect (RITE), conductive hyperthermic chemotherapy, and electromotive drug administration (EMDA) chemotherapy. Depot delivery devices, which enable the slow release of chemotherapy over an extended period of time, have been reported and are in early phase development 18, 19 . In this Review, we describe the evidence for intravesical device-assisted technologies and summarize their efficacy, safety, and tolerability outcomes. We also highlight other potential devices that are promising for the treatment of NMIBC.
Hyperthermia as a treatment
The use of hyperthermia to treat bladder cancer is based on the concept that heat can potentiate the effect of chemotherapy 20 . In vitro studies demonstrated that hyperthermia results in the denaturation of cytoplasmic structures and enzymatic proteins, inducing cell death by apoptosis and necrosis [21] [22] [23] . Temperature elevation enhances cell membrane permeability, resulting in increased drug absorption 24, 25 . Hyperthermia also causes the release of heat shock proteins (HSPs), particularly HSP70, during cellular necrosis, which stimulates an adaptive T cell response to induce the innate and adaptive immune system, despite promoting thermotolerance 26, 27 . Furthermore, at 42 °C, exponential cell death seems to occur; above this temperature the benefit of hyperthermia increases marginally, but toxic effects might become apparent 21 . Cancer cells are more susceptible to hyperthermia than nonmalignant cells, and, in clinical practice, hyperthermia is usually delivered at 42 °C, although 45 °C has been described 28 ( Fig. 1 ). Data from cell lines demonstrate synergism, whereby the effect of hyperthermia plus chemotherapy is greater than the combined additive effect 29, 30 . Hyperthermia might also chemosensitize tumours to alkylating agents such as MMC via HSP-mediated pathways 26 .
In the clinical setting, hyperthermia has been used in combination with chemotherapy for the treatment of NMIBC [31] [32] [33] . Hyperthermia can be delivered by either intravesical radiofrequency-induced hyperthermia or conductive heat via energy transfer from heated circulating fluid [31] [32] [33] . Deep regional hyperthermia by radiofrequency is feasible and has been reported but is not in widespread use in clinical practice, although it might be effective in MIBC as well as NMIBC 34 . RITE Radiofrequency-induced hyperthermia is an established therapy for a number of cancers, including hepato cellular carcinoma 35 , Barrett oesophagus 36 , breast cancer 37 , and lung cancer 38 . Radiofrequency is delivered to tissues with high perfusion and poor electrical and thermal conductivity at a frequency of 350-500 kHz for the treatment of localized solid organ tumours 39, 40 . By contrast, RITE is delivered to the entire bladder at a frequency of 915 MHz using microwave radiation, which does not require conductive delivery of energy and can penetrate low-conductive tissues 40 . This modality is ideal for the delivery of heat energy directly to the tissue to enable an efficient effect on the full bladder wall thickness. Pharmacokinetic analysis showed that RITE with 40 mg MMC over 60 minutes resulted in >10-fold higher MMC concentration in bladder cancer tissue than passive intravesical MMC (median 665 ng/g versus 64 ng/g, P = 0.018) 41 . Plasma concentrations of MMC in patients treated using RITE plus MMC increased rapidly within 15 minutes and continued to increase and peak between 45 and 60 minutes 42 . In comparison, a doseresponse increase in patients treated with passive MMC was observed, in which plasma concentration peaked at 15 minutes and remained stable over 60 minutes 42 . In addition, a report by Ware et al. 43 suggested that radiofrequency promotes the formation of tunnelling nanotubes within cancer cells, which might increase drug diffusion and increase efficiency 43 . RITE therapy for bladder cancer is the most established device-assisted therapy, and the Synergo system was first reported in 1995 (reF. 44 ). The Synergo system comprises a microwave radiofrequency source generating energy at 915 MHz and an antenna located at the tip of a Foley catheter, which delivers radiofrequency to the bladder wall (Fig. 2) . The specialized triple-lumen 18/20 Fr Foley catheter consists of the inflow lumen and the outflow lumen, an energy source antenna, and intravesical thermocouples at the catheter tip and proximal urethra that are used to monitor bladder wall temperature 44 . The radiofrequency antenna delivers hyperthermia at 42 ± 2 °C to the bladder wall by direct
Key points
• Intravesical chemotherapy and BCG are the recommended adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC) to reduce the risk of disease recurrence.
• The combination of BCG supply shortage and alternative bladder-sparing approaches in patients with BCG-refractory disease has led to the development of hyperthermia-inducing device-assisted therapies for NMIBC.
• Radiofrequency-induced thermochemotherapeutic effect (RITE), hyperthermic conductive chemotherapy, and electromotive drug administration (EMDA) chemotherapy are the most widely used devices to augment intravesical chemotherapy.
• Randomized controlled trials suggest that RITE and alternating BCG and EMDA mitomycin C are more efficacious than BCG alone. Data on patients with concurrent carcinoma in situ treated with RITE are currently inconclusive.
• Adverse events from RITE, hyperthermic conductive chemotherapy, and EMDA chemotherapy are short-lived and better tolerated than BCG.
• Other novel therapies that improve the delivery of chemotherapy by prolonging chemotherapy exposure time or targeted local therapy are promising.
www.nature.com/nrurol or pre-TURBT ablative treatment [59] [60] [61] [62] [63] . Only 4 randomized controlled trials (RCTs) investigating RITE have been conducted; 3 as adjuvant treatment 31, 47, 54, 58 and 1 in the ablative setting 49 . Reported recurrence-free survival (RFS) differs between studies, reflecting the heterogenous patient cohorts, follow-up duration, different treatment regimens, and presence of carcinoma in situ (CIS). In studies including patients with papillary-only disease, RFS ranges from 53-91% with a 9.6-24.0-month follow-up duration 31, 47, [56] [57] [58] 62, 63 . However, in patients who had isolated or concurrent CIS (13-68%), RFS ranged from 29−88.6% at 14-38-month follow-up duration 46, 47, 52, 53, 55, [59] [60] [61] . A substantial number of patients treated with RITE developed recurrence after previous intravesical therapy, and disease progression occurs in 0-38% of patients 31, 47, 48, 51, [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] . In the pre-TURBT ablative setting, data from nine studies reporting outcomes from 211 patients suggest a complete response rate of 65.4% 3, 44, 48, 50, [60] [61] [62] [63] . Subsequent studies have used an increased dose of MMC for ablative therapy (two 30-minute cycles of 40 mg MMC as opposed to 20 mg MMC), which might be beneficial for patients with widespread concurrent or isolated CIS [59] [60] [61] [62] [63] . In one RCT of 52 patients, RITE resulted in significantly higher complete response rates than MMC alone (66% versus 22%, P < 0.01) 49 . Three RCTs compared RITE with either passive MMC or BCG: two trials in the setting of first-line therapy and one in patients who had experienced BCG failure. Colombo et al. 58 conducted an RCT involving radiation while the inflow and outflow channels recirculate chemotherapy at room temperature (22 °C) within a closed system. Treatment comprises two 30-minute sessions; between each session, the bladder is emptied, and a new solution of MMC is instilled, reducing the dilutional effect of diuresis 45 . An adjuvant treatment protocol consists of two 30-minute sessions of 20 mg MMC instillations dissolved in 40 ml of saline or water. An ablative protocol of two 30-minute sessions of 40 mg MMC in 40 ml of saline or water is recommended in the manufacturer's protocol 46 .
The requirement for intravesical administration of MMC halfway into the treatment session with RITE requires additional nursing input. An induction protocol of six-toeight once-weekly treatments is administered followed by a maintenance protocol of one treatment every 6 weeks for the first year and one treatment every 8 weeks for the second year 47 . An alternative protocol consisting of six once-weekly instillations as an induction protocol with a maintenance protocol of three once-weekly instillations at 3, 6, and 12 months has been reported 31 . No comparisons can be made between the two protocols, as they have been tested in different patient cohorts.
Efficacy. To date, 21 reports from 20 studies on the efficacy of RITE for NMIBC have been published (Table 1) ; 5 studies report outcomes for RITE delivered in the pre-TURBT ablative setting 3, 44, [48] [49] [50] , 9 studies were conducted in the adjuvant setting 47, [51] [52] [53] [54] [55] [56] [57] [58] , and 6 studies had a mixed cohort of patients treated with adjuvant therapy Nature reviews | Urology R e v i e w s [21] [22] [23] . Temperature elevation enhances cell membrane permeability , leading to increased drug absorption 24, 25 . Hyperthermia also causes the release of heat shock proteins (HSPs), in particular HSP70, during cellular necrosis, which stimulates an adaptive T cell response to induce the innate and adaptive immune system 26, 27 . At 42 °C, exponential cell death seems to occur ; above this temperature, the benefit of hyperthermia might be minimal but toxic effects might become apparent
21
. Cancer cells are more susceptible to hyperthermia than nonmalignant cells. Radiofrequency-induced thermochemotherapeutic effect (RITE) has been shown to promote the formation of nanotubes on the cancer cell membrane to allow intracellular delivery of chemotherapy 43 .
83 patients comparing RITE plus MMC with passive MMC in intermediate-risk or high-risk disease. Patients in both arms (42 in the RITE arm and 41 in the passive MMC arm) had complete TURBT followed by an induction schedule of eight once-weekly intravesical instillations and a maintenance schedule of four once-monthly instillations. Patients in the RITE arm received two 30-minute sessions of MMC (20 mg in 40 ml saline), and patients in the passive MMC arm received 40 mg of MMC in 40 ml saline for 1 hour. At 24 months, RFS was significantly improved in patients who received RITE (RITE: 82.9% versus passive MMC: 42.5%, P = 0.002) with no significant difference in disease progression between treatment arms 58 . Subsequently, a longer-term follow-up of a median of 91 months suggested that the RFS superiority of RITE to passive MMC is sustained (RITE: 60% versus passive MMC: 20%, P < 0.001) 54 . Arends et al. 31 subsequently reported an RCT of 190 patients with intermediate-risk or high-risk NMIBC (92 patients received RITE plus MMC and 98 patients received BCG). Patients in the RITE arm received a six once-weekly induction course of two 30-minute sessions of 20 mg of MMC in 50 ml of water followed by a three once-weekly maintenance course at 3, 6, and 12 months, whereas patients in the BCG arm received full dose OncoTICE for 120 minutes per session for six once-weekly induction instillations and three onceweekly maintenance instillations at 3, 6, and 12 months. The trial closed early owing to slow recruitment. Intention-to-treat results for the whole patient cohort were not reported. At the 24-month follow-up point, a trend towards significance in RFS was observed in the RITE arm (n = 71) compared with the control arm (n = 76) for patients with papillary-only disease (RITE: 78.1% versus 64.8%, P = 0.08). The per-protocol analysis suggested that the RFS was significantly higher in the RITE arm than the BCG arm for patients with papillary disease (RITE: 81.8% versus BCG: 64.8%, P = 0.02). At 3 months, the complete response rate for patients with CIS was not significantly different between the two arms. This study was the first to compare RITE plus MMC with BCG therapy, and although the primary outcome was not met in the intention-to-treat analysis, the results suggest that RITE is an effective treatment for papillary NMIBC. These results are promising, but the outcomes for patients with CIS-only disease or concurrent CIS remains unreported.
Tan et al. 47 The Synergo system comprises a radiofrequency generator, which delivers radiofrequency energy at 915 MHz; a drug circulation unit, which promotes the circulation of chemotherapy from the device to the bladder within a closed system and vice versa; and a computer system with application-specific software. The specialized triple-lumen silicon catheter has a lumen to fill the balloon at the catheter tip and an inflow channel and an outflow channel. At the distal end of the catheter, thermocouples are in contact with the bladder wall for accurate temperature measurement, as well as the miniaturized antenna, which delivers radiofrequency to the bladder wall. CIS, carcinoma in situ; CR , complete response; DFS, disease-free survival; EMDA , electromotive drug administration; MMC, mitomycin C; NA , not applicable; NMIBC, non-muscle-invasive bladder cancer ; RCT, randomized controlled trial; RFS, recurrence-free survival; RITE, radiofrequency-induced thermochemotherapeutic effect; TURBT, transurethral resection of bladder tumour.
Nature reviews | Urology R e v i e w s 46 . The DFS in patients who received this protocol was 43% at a median follow-up period of 22 months 46 . The requirement for an increased MMC dose in the ablative setting might explain the results observed in the HYMN study.
The rate of disease progression in the HYMN trial was low (8%) at a median follow-up duration of 35 months, which should be compared with the 5% risk of 90-day mortality of radical cystectomy in these patients who have comorbidities 64 . Despite limited RCT data, emerging evidence suggests that RITE plus MMC is a suitable alternative intravesical treatment option to passive MMC. Moreover, this modality could be considered for patients with high-risk papillary NMIBC as an alternative to BCG in the first-line setting. Results following RITE plus MMC treatment in patients with papillary-only disease who experienced BCG failure suggest that this modality might be promising, but evidence is currently insufficient to support its use in patients with CIS. In fact, the FDA defined that a RFS of ≥25-30% at 18-24 months is clinically meaningful in patients with BCG-refractory disease 65 . Both treatment arms in HYMN achieved a RFS >35%, which is above the threshold for clinically meaningful effect, although patients experiencing BCG failure recruited to HYMN had a better prognosis, as BCG-intolerant and relapsing patients were also included.
Adverse events. The reported adverse event rates following RITE suggest that it is well tolerated, with 92% of patients completing induction treatment 66 . The most commonly reported adverse events during treatment are cystitis and/or storage lower urinary tract symptoms (LUTS) (32%), suprapubic pain (30%), and bladder spasm (20%) 44, 47, [49] [50] [51] 53, [55] [56] [57] [58] [59] [60] 62, 63 . Storage LUTS, such as incontinence (12.6%), nocturia (23.9%), and haematuria (17.2%), are the most common adverse events after treatment, and 3.3% of patients had urethral stricture (Table 2) . However, most adverse events are self-limiting and short-lived 31, 47 . RITE recirculates room-temperature MMC; hence, no thermal reaction to the urethra occurs, which would theoretically minimize the risk of urethral strictures 50 . Iatrogenic urethral injuries owing to catheter insertion might have contributed to the development of the urethral strictures reported. Thermal reaction on the posterior bladder wall, which is commonly observed following RITE treatment, can look suspicious for CIS owing to urothelium erythema and prompt unnecessary bladder biopsies, although they are benign and do not cause long-term damage 44 . Indeed, animal studies suggest that the thermal reaction represents focal oedema, haemorrhage, and oedema of the lamina propria and serosa, which resolves completely 67 . Adverse events reported in RCTs enable comparison of adverse event rates following RITE plus MMC or other standard-of-care treatment (Supplementary Table 1 ). RITE resulted in significantly more pain (P < 0.001) and bladder wall erythema (P < 0.001) than passive MMC, but no difference in dysuria, haematuria, urethral stenosis, or allergic reaction was observed 58 . Patients who received RITE plus MMC had a substantially increased risk of bladder pain during treatment (OR 26. In summary, RITE treatment for bladder cancer has been shown to be efficacious in intermediate-risk or high-risk, papillary-only, BCG-naive NMIBC in a randomized setting. In the BCG-failure setting, subgroup analysis of patients with papillary-only disease showed improved efficacy in RITE-treated patients compared with controls, but this difference was not significant. Thus, this modality might be a treatment option in this patient cohort with limited options. Data specifically in the BCG-refractory setting and in patients with isolated or concurrent CIS are limited, but future planned trials will hopefully address this question. A single-arm study, RITE-Europe, which will recruit patients with BCG-refractory CIS with or without papillary NMIBC, is being planned and treatment will consist of RITE with two 30-minute sessions of 40 mg MMC.
Conductive hyperthermic chemotherapy
Conductive hyperthermic chemotherapy is an alternative technology for delivering localized hyperthermia. The chemotherapy solution is externally heated and recirculated at a constant temperature via a catheter www.nature.com/nrurol irrigation channel to deliver hyperthermia to the bladder wall by conduction 68 . Before its application in the treatment of NMIBC, conductive hyperthermia was adopted as hyperthermic intraperitoneal chemotherapy (HIPEC), which is an approved treatment used in combination with cytoreductive surgery for peritoneal metastasis in ovarian, gastric, and colorectal cancer [69] [70] [71] . Two conductive hyperthermic chemotherapy systems for bladder cancer have been reported, both of which use MMC: the Combat Bladder Recirculating System (BRS) and the Unithermia system. Minimal nursing hands-on time is required once the system is set up, as a midtreatment repeat instillation of MMC is not required, enabling a lower nurse-to-patient ratio than is required for RITE. The Combat BRS uses a 16 Fr three-way Foley catheter, which recirculates MMC in a closed system with a bubble trap (Fig. 3) . MMC is heated to 43 °C using an aluminium heat exchanger that enables efficient heat transfer and accurate temperature control within ±0.5 °C. Each treatment uses 40 or 80 mg MMC in 50 ml of water for adjuvant and ablative treatment, respectively, recirculating for a continuous 60 minutes 32, 68, 72 . The Unithermia system uses a conical heat exchanger with a high recirculation rate to deliver hyperthermic MMC to the bladder via an 18 Fr Foley catheter. MMC is heated to 46.5 °C to deliver it at 44.5 °C to the bladder wall. The system is primed with 40 mg of MMC in 50 ml of water, which is recirculated for a continuous 50 minutes 33, 72 . Results of a pharmacokinetics study suggested that peak plasma MMC concentration is achieved around 45 minutes after MMC instillation 73 . Aqueous doxorubicin has been shown to be efficacious for the treatment of NMIBC 74 . The synergism between hyperthermia and temperature-activated liposomes has been shown to enable a much increased dose of drug to be delivered at the target organ of treatment 75 . ThermoDox is a heat-activated liposomal encapsulation of doxorubicin that is a promising alternative to MMC. At 40-45 °C, the liposomes release doxorubicin directly at the heated source, which enables a targeted approach 76 . Total percentages have been calculated by taking the sum of patients reporting a specific adverse event divided by the total number of patients of each study in which the specific adverse event is reported.
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An in vivo study in pigs showed that intravenous ThermoDox with localized conductive hyperthermia delivered to the bladder resulted in a 10-fold higher concentration of doxorubicin within the bladder than when ThermoDox was not heated or intra venous doxorubicin was used 76 . Although heat-activated, ThermoDox is infused intravenously, and patients with a history of cardiac disease might not be suitable candidates for this therapy owing to the cardiotoxic nature of doxorubicin, although reports suggest that this is not so apparent in the liposomal-based formulation 77, 78 . In total, five studies have reported results for conductive hyperthermia 32, 33, 68, 72, 79 , and although RCTs are in progress, level 1 evidence reporting outcomes for conductive hyperthermia for the treatment for NMIBC is lacking.
Efficacy. All reports to date are single-arm observational studies; two using the HIVEC system 32, 68 and three using the Unithermia system 33, 72, 79 , all of which use MMC (Table 3 ). All studies conducted to date included patients with predominantly intermediate-risk NMIBC and were proof-of-concept studies with a limited sample size of between 15 and 43 patients. Studies using the HIVEC system report a RFS of 87.5% at the 24-month follow-up point in an adjuvant setting (n = 16) 32 and a complete response rate of 60-63% after eight once-weekly ablative intravesical treatments (n = 39) 32, 68 . The three studies using the Unithermia system included 117 patients and report a RFS of 65-70% at follow-up points between 24 and 41 months 33, 72, 79 . These studies included one retrospective propensity-score-matched comparison 79 , which reported that patients treated with BCG had a better RFS than those treated with conductive hyperthermia (89.5% versus 70.1%, P = 0.054) 79 . No difference in disease progression was reported.
Adverse events. Similar to RITE, conductive hyperthermia therapy is well tolerated, and most adverse events are short-lived 80 (Table 4) . Reliable adverse event data are available for the HIVEC system. An interim analysis of adverse events in 307 patients recruited into HIVEC-I and HIVEC-II reported that 89% of patients completed a minimum of induction therapy compared with 95% of patients treated with passive MMC 80 . In the patients treated with HIVEC, the most common adverse events were urinary frequency (15%), suprapubic pain (13.1%), haematuria (11.8%), and urinary urgency (11.8%) 80 . HIVEC was associated with significantly increased incidence of urinary frequency (15.0% versus 5.8%, P = 0.008), haematuria (11.8% versus 3.9%, P = 0.010), and bladder spasm (6.5% versus 0.6%, P = 0.006). No significant difference in grade III adverse events between HIVEC (2.3%) and passive MMC (1.5%) were observed, and these events were predominantly caused by allergic reactions. No urethral strictures occurred in either treatment arm 80 . The safety and efficacy data for the Unithermia system are not well reported, and, at present, the grade III adverse event rate is 12% (Table 5 ). Noninfective cystitis (37.2%) is the predominant reported adverse event, followed by suprapubic pain (23.3%), and bladder spasm or urinary urgency (22.1%). Notably, one incidence of bladder perforation occurred following Unithermia treatment, resulting in a grade IV adverse event, which was reported by Ekin and colleagues 33 . Reasons for this occurrence remain uncertain but might be related to the increased circulation rate of fluid and temperature used.
Prospective randomized data are eagerly awaited. HIVEC-I (EudraCT: 2013-002628-18) 81 and HIVEC-II (ISRCTN: 23639415) 82 . Both studies completed patient recruitment at the end of 2017 and will report their results in due course.
EMDA MMC
EMDA enhances the delivery of chemotherapy by electro-osmosis, iontophoresis, and electroporation, whereby an electrical charge is generated between a catheter electrode and a cutaneous electrode to aid the transport of drug molecules into tissues 83, 84 . In vitro studies have shown that EMDA MMC delivers a sixfold greater concentration of MMC to the bladder wall than passive diffusion, reaching a peak concentration of MMC within 15 minutes of initiating treatment 83, 84 . MMC was detected in all layers of the bladder wall in both treatment modalities; however, MMC concentration in the urothelium was 30-fold greater using EMDA MMC than passive MMC and threefold greater in the lamina propria and muscularis 83 . Intravesical EMDA MMC is administered using a battery-powered generator to deliver a controlled electric current of up to 30 mA. The electrical current passes between the intravesical active electrode at the tip of a catheter to a dispersive ground electrode positioned on the lower abdomen (Fig. 4) . The specialized 16 Fr catheter is inserted, and the bladder is washed with water, after which 40 mg MMC in 100 ml of water is instilled, with the operating current maintained at 20 mA pulsed electrical current. Treatment time is 30 minutes per session, which is shorter than that of RITE and conductive hyperthermia, and cadaveric studies suggest that the peak concentration of MMC in the bladder wall is achieved after 15 minutes of initiating treatment 83 .
Efficacy. To date, seven studies have reported on the efficacy of EMDA MMC for bladder cancer, three of which investigated neoadjuvant EMDA MMC as a monotherapy or in combination with BCG 3,4,85 and four of which were in the adjuvant setting [86] [87] [88] [89] (Table 6 ). Four studies reported outcomes for monotherapy EMDA MMC 3, 4, 85, 88, 89 , including one RCT in the neoadjuvant setting 4 and one in the adjuvant setting 88 . Alternating BCG with EMDA MMC is a more established regimen than EMDA MMC as monotherapy, and promising results from an RCT and another single-arm study have been reported 86, 87 . Di Stasi et al. 87 randomized patients with high-risk NMIBC to either sequential BCG plus EMDA MMC or BCG alone. DFS was higher in the BCG plus EMDA MMC group than in the BCG alone group at 88 months (58.1% versus 42.1%, P = 0.0012) 87 . Progression-free survival (PFS; 90.7% versus 78.1%, P = 0.004) and overall survival (78.5% versus 67.6%, P = 0.045) were also significantly improved in the BCG plus EMDA MMC cohort. However, the BCG plus EMDA MMC arm had an induction protocol of NA , not applicable; NMIBC, non-muscle-invasive bladder cancer ; NR , not reported; UTI, urinary tract infection. a Total percentages have been calculated by taking the sum of patients reporting a specific adverse event divided by the total number of patients of each study in which the specific adverse event is reported. Total percentages have been calculated by taking the sum of patients observing a specific adverse event divided by the total number of patients of each study in which the specific adverse event is reported.
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nine once-weekly treatments compared with the six once-weekly treatments in the BCG alone arm, and the increased number of induction treatments might have improved the efficacy. A subsequent single-arm study using the same BCG plus EMDA MMC treatment regimen reported a 71% RFS and 95% PFS at 24 months 86 . The proposed hypothesis for combination therapy is that instilling BCG first results in BCG-induced inflammation, which might increase urothelium permeability to MMC. The results for BCG plus EMDA MMC are impressive, but further validation is required before it is accepted as standard of care.
In the monotherapy setting, a three-arm study randomized patients to EMDA MMC, BCG, or passive MMC 88 . Patients treated with EMDA MMC had a significantly longer time to recurrence than those who received passive MMC or BCG (EMDA MMC: 35 months versus MMC: 20 months versus BCG: 26 months, P = 0.013). However, no difference in time to disease progression was observed. Complete response rate at 6 months was higher in the EMDA MMC (58%) and BCG (64%) groups than in the passive MMC group (31%) (P = 0.012).
Di Stasi et al. 4 reported outcomes of a trial in which patients were randomized to either TURBT alone, preoperative EMDA MMC followed by TURBT, or TURBT with a single postoperative instillation of passive MMC 4 . At a median follow-up duration of 86 months, patients in the preoperative EMDA MMC group had significantly higher RFS than those in the TURBT alone and TURBT with postoperative passive MMC groups (62% versus 36% versus 41%, P < 0.001) 4 . Colombo et al. 3 compared ablative treatment with RITE, passive MMC, and EMDA MMC in a nonrandomized study, which showed that the complete response rate was 66%, 27.7%, and 40%, respectively 3 .
Adverse events. Similar to hyperthermia delivery systems, 90% of patients complete adjuvant induction treatment of EMDA MMC (Table 7) . In an RCT comparing EMDA MMC, passive MMC, and BCG, significantly more local and systemic adverse events occurred in patients who received BCG than in those in the two MMC arms 88 . EMDA MMC had lower drug-related cystitis incidence (36% versus 67%, P = 0.001), haematuria (22% versus 72%, P = 0.001), frequency (19% versus 58%, P = 0.001), and fatigue (2.5% versus 44.4%, P = 0.001) than BCG 88 . Pooled adverse events from 73 patients suggest that drug-related cystitis and/or storage LUTS (23%), bladder spasm (19%), and haematuria (12%) were the most common adverse events, and no urethral strictures were reported 85, 88, 89 . The most common reason for stopping EMDA MMC treatment was allergic reaction 87 . Compared with RITE plus MMC, EMDA MMC has an increased rate of suprapubic pain and dysuria, and patients who received RITE experienced less urinary frequency 3 . Anecdotally, subcutaneous burns have been reported to develop where the ground electrode pad is placed.
No differences in reported adverse events were seen when sequential therapy of BCG-EMDA MMC was compared with BCG 87 . Between 3% and 28% of patients treated with combination BCG and EMDA MMC could not tolerate the complete course of nine induction instillations 86, 87 . LUTS, haematuria, and inability to tolerate the catheter were the most frequent reasons for early termination of treatment 86 . Despite level 1 evidence reporting the superiority of EMDA, particularly when used in combination with BCG, compared with BCG and MMC, the use of EMDA has been limited in the treatment of NMIBC. A Cochrane review highlights that the quality of Nature reviews | Urology • MMC: 27.7
• RITE: 66
• EMDA: 40 NA evidence in these studies was low and that data on time to recurrence and progression as well as adverse events remain inconclusive, suggesting that further studies are warranted 90 .
Comparison of cost between treatments
Comparison of the estimated cost of treatment (disposables and drugs) between the different intravesical device-assisted therapies based on end-user price suggest that RITE treatment is the most expensive, followed by the EMDA and conductive hyperthermia systems (Table 8 ). The estimated cost of treatment was based on published treatment protocols. The costs of procuring the different devices themselves as well as the service contract, if applicable, are normally the subject of separate negotiation and have not been reported herein. Physician and nurse costs to deliver treatment and other associated costs have been excluded. The disposables for the RITE and EMDA systems are more costly than those for conductive hyperthermic chemotherapy owing to the requirement of specialized catheters such as a radiofrequency antenna with thermocouples for the RITE catheter or active electrode at the catheter tip for the EMDA catheter. The different maintenance protocols used between different treatment devices makes comparison of cost difficult.
The only cost-effectiveness analysis that has been performed was reported in the RCT comparing BCG plus EMDA MMC with BCG alone 87 . On the basis of a Markov model, sequential therapy was more costly than BCG therapy alone, but it was more efficacious, with a 5-year increment cost-effectiveness ratio (ICER) of Can$27,815 per life-year gained (US$21,173, assuming Can$1 = US$0.76) 91 . This figure is below the maximum acceptable ICER of £20,000-30,000 (US$26,472-39,709, assuming £1 = US$1.32) per quality-adjusted life-year (QALY) used by the UK National Institute for Health and Care Excellence (NICE) and the US$50,000 QALY used as a benchmark of acceptability when evaluating new technology 92, 93 . Nature reviews | Urology R e v i e w s . GemRIS is delivered into the bladder using an 18 Fr ureteric catheter-like inserter. The 5-cm-long device, which folds into a pretzel shape, remains in the bladder and releases gemcitabine by a passive osmotic delivery mechanism over a 7-day period 18 (Fig. 5) . The device can be removed 7 days later by grasping forceps and flexible cystoscopy 18 . In a phase 1b study (NCT02722538) 94 , the GemRIS pretzel was well tolerated by all 10 patients with MIBC. Neoadjuvant GemRIS treatment for 14 days before radical cystectomy for all 10 patients resulted in a reduction of tumour size in 80% of patients, with 40% having pT0 disease after treatment 18 . VesiGel is a reverse-thermal gelation hydrogel compound combined with high-dose MMC that is liquid at room temperature and fully solidifies to a gel state www.nature.com/nrurol R e v i e w s at body temperature within 15 minutes after instillation. VesiGel can be delivered using a standard Foley catheter and gradually dissolves over several hours while releasing MMC. This slow-release preparation might be more effective than a single 1-hour instillation of aqueous MMC. In a study of 64 patients with low-grade NMIBC treated with either VesiGel 0.06% (40 mg in 64 ml), VesiGel 0.12% (80 mg in 64 ml), or MMC 0.1% (40 mg in 40 ml water) as chemoablation therapy, VesiGel 80 mg had a higher complete response rate (87.5%) than aqueous MMC 40 mg (63.6%) and VesiGel 40 mg (35.3%) 19 . The results of this proofof-concept study are promising, and future studies will be necessary to determine the effect of drug delivery and RFS in the adjuvant setting 19 . Although the results for VesiGel 80 mg are promising, interestingly, aqueous MMC 40 mg had a better complete response rate than VesiGel 40 mg, suggesting that a slow-release formulation might take longer to reach peak chemotherapy concentration, and this delay might negate the advantage of prolonged drug exposure, requiring an increased drug concentration. Early safety and Conclusions Intravesical hyperthermia-inducing device-assisted therapies are attractive treatment options for augmenting the efficacy of intravesical chemotherapy for the treatment of NMIBC. Prospective randomized trials for RITE suggest that it might be superior to BCG in papillary-only disease in both BCG-naive and BCG-failure cohorts. However, results remain inconclusive for patients with isolated CIS or papillary disease with concurrent CIS. RCTs comparing conductive hyperthermia plus MMC with passive MMC alone have reached their recruitment target, and results are eagerly awaited before adoption of intravesical device-assisted therapies in clinical practice can be recommended. Results of RCTs of BCG-EMDA MMC, in both the ablative (neoadjuvant) and adjuvant setting, are impressive, but this modality has not been widely adopted and will require further validation. Reported adverse events suggest that they are short-lived and not significantly worse than those of intravesical BCG. Hence, these treatments are normally administered in a nurse-led environment. The induction regime of these treatments is now standardized to mirror traditional intravesical chemotherapy and BCG, but the maintenance treatment requirement and protocol have considerable variation. Other novel treatment options that increase intravesical chemotherapy contact time have shown promising results in phase I trials. With the issues with BCG supply in some countries, the use of device-assisted therapies is expected to increase.
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Slow release of gemcitabine by a passive osmotic delivery mechanism over 7 days tolerability data suggest that VesiGel is well tolerated, with similar reports of allergic reaction to aqueous MMC, although the incidence of dysuria was higher (40% versus 13%) 95 .
